Gilead Sciences, Inc. last reported quarterly results on Oct 29, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $8.3 billion (+6.8% year over year) and diluted EPS of $1.94. It usually reports 29–41 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 9, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Feb 10, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 29–41 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 29, 2026
29 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
8,300
+6.8%
|
2,429
-20.4%
|
1.94
-20.2%
|
|
Aug 4, 2026
35 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
7,803
+10.2%
|
-10,496
-635.5%
|
-8.45
-641.7%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
6,960
+4.4%
|
2,021
+53.7%
|
1.61
+54.8%
|
|
Feb 10, 2026
41 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
7,925
+4.7%
|
2,183
+22.4%
|
1.74
+25.0%
|
|
Oct 30, 2025
30 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
7,769
+3.0%
|
3,052
+143.6%
|
2.43
+143.0%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
7,082
+1.8%
|
1,960
+21.4%
|
1.56
+20.9%
|
|
Apr 24, 2025
24 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
6,667
-0.3%
|
1,315
+131.5%
|
1.04
+131.1%
|
|
Feb 11, 2025
42 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
7,569
+6.4%
|
1,783
+24.8%
|
1.39
+22.5%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- GILD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Foster City, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 882095
- Former names
- GILEAD SCIENCES INC (until Feb 17, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.